Dra. Elena Buendia Gonzalez

• Médico Interno residente en Hospital Virgen de la Salud de Toledo 2005-2010
• FEA en Servicio de Urología en Toledo como especialista en URO Oncología 2010-2014
• Miembro de la Unidad de Trasplante desde 2008- OCT 2014
• FEA En Servicio de Urología en Hospital Universitario Fundación Jiménez Díaz Desde Oct 2024 hasta la actualidad
• Miembro de la Unidad de Uro-Oncología dedicada al Cáncer de Urotelio desde 2016

Especialista en Cirugía Laparoscópica y Robótica del Carcinoma Urotelial.

• 2025 42756493BLC1003: Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer. Janssen Research & Development, LLC. EU CT Number: 2021-004144-22. Principal Investigator.
• 2024 UTOPIA: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients with Low Grade (LG) Non muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence. UroGen Pharma Ltd. IND: 167943. EU CT Number: 2023-507261-25. Sub-Investigator.
• 2023 ORION: A Phase 3, Single-Arm Study to Evaluate the Efficacy and Safety of Oncofid-P-B (Paclitaxel-Hyaluronic Acid Conjugate) Administered Intravesically to Patients with Bcg-Unresponsive Carcinoma In Situ of The Bladder With Or Without Ta-T1 Papillary Disease. Eudra Ct N: 2022-001236-28. Fidia Farmaceutici S.P.A.
• Sub-Investigator.
• 2023 SSANTROP. A Phase 2 prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG-unresponsive NMIBC patients.. Protocol code: APRO07-2022. EudraCT No: 2022-002998-28. APRO.
• Sub-investigator.
• 2022 ENVISION: A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients with Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence. UroGen Pharma Ltd. IND 138749. Sub-Investigator.
• 2022 ALBAN: An open label, randomized, phase 3 trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus Calmette Guerin) bladder instillation in BCG-naive patients with high-risk non-muscle invasive Bladder Cancer. UNICANCER Group Tumor: GETUG / AFU. Protocol n° UC-0160/1717 (AFU-GETUG 37)EudraCT n°: 2017-004512-19. Sub-Investigator.
• 2021 URANUS TRIAL: Neo-adjuvant versus Adjuvant chemotherapy in Upper tract Urothelial Carcinoma: A feasibility phase 2 randomize clinical Trial. Sub-Investigator. EUOG (European Uro-oncology Group). Principal Investigator.
• 2019 ENCORE-01: Phase I2b Clinical Trial: Treatment of high-risk non-muscle infiltrating bladder tumors with IMUNO BCG Moreau RJ as prophylaxis for recurrence and progression. Sub-Investigator.

• Consequences of BCG shortage for endovesical instillation and its effect on recurrence-free survival in high-risk non-infiltrating bladder tumours. X. Pérez Aizpurua, Juan Ignacio Monzó Gardiner, J. Maqueda Arellano, E. Buendía González, Leslie Cuello Sánchez, J.J. Tufet Jaumot. Anales de la Real Academia Nacional de Medicina, ISSN 0034-0634, Nº 138, 3, 2021, págs. 237-245.
• A Systematic Review on the Current Landscape of T1 Bladder Cancer Substaging. Pérez-Aizpurua X, Monzó-Gardiner JI, Popescu OB, Buendía-González E, Cuello- Sánchez L, Cañadas-Granados M, Tufet I Jaumot JJ, Ruiz de Castroviejo-Blanco J, Osorio-Ospina F, Cabello-Benavente R, González-Enguita C Urology. 2024 Dec;194:310-326. doi: 10.1016/j.urology.2024.10.013. Epub 2024 Oct 9. PMID: 39389368.
• BCG shortage for intravesical instillation is associated with early tumoral recurrence in patients with high-risk non-muscle invasive bladder tumours. Pérez-Aizpurua X, Monzó-Gardiner JI, Maqueda-Arellano J, Buendía-González E, Cuello-Sánchez L, Tufet I Jaumot JJ, Alonso-Román J, Gómez-Jordana Mañas B, Ruiz de Castroviejo Blanco J, Osorio Ospina F, Cabello Benavente R, González-Enguita C Actas Urol Esp (Engl Ed). 2023 May;47(4):250-258. English, Spanish. Doi: 10.1016/j.acuroe.2023.01.005. Epub 2023 Feb 6. PMID: 36754206.
• Cólico renal. Opciones terapéuticas actuales. Beneficios de la litotricia extracorpórea inmediato o précoz (leoci). González Enguita C, Bueno Serrano G, Tabares Jiménez, J, Charry Gónima P, Buendía González E.. Cuadernos de Urología. Temas de Formación para el Médico de Atención Primaria. AÑO 2015, N º 68, 2015. NISSN 1135-3163
• Otras 5 publicaciones libros y revistas nacionales.

Colaborador clínico docente. Moderadora en Congreso Nacional 2021,2022,2023,2024

Acreditación como Cirujano Robótico Nov2024